# PLUS THERAPEUTICS, Inc. (PSTV) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PSTV
## Company Profile
- Ticker: PSTV
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Stem Cells, Oncology
## Stock Data
- Close: 3.87 USD
- Market cap: 37654916.589999996 USD
- Last updated: 2026-07-31
## Business Overview
PLUS Therapeutics is an oncology company focused on radiotherapeutics and targeted treatment delivery for cancer. Its story is built around the use of radiation-based approaches to address hard-to-treat tumors.
## Why The Stock Is Moving

Current closing-price context is not available for PSTV.

## Geographic Base

PLUS Therapeutics is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology biotechnology.

## Business Model

The company depends on clinical progress, regulatory steps, and the ability to prove its delivery strategy can improve cancer outcomes. Investors usually track readouts, manufacturing, and financing.

## Landscape Position

PLUS Therapeutics occupies a niche radiotherapy position within biotech. The stock is catalyst-sensitive because its value depends on narrow oncology programs and execution.

## Future Catalysts

- PLUS Therapeutics’s catalysts are Rhenium-based oncology programs and any clinical or regulatory update that keeps the platform moving. The company remains highly dependent on proof of concept.

## Recent News
- 2026-06-04 11:30 EST — [Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory](https://biopharmsignal.com/news/PSTV/plus-therapeutics-announces-cap-accreditation-of-cnsider-diagnostics-clinical-laboratory) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-26 11:30 EST — [Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases](https://biopharmsignal.com/news/PSTV/plus-cnside-diagnostic-platform-demonstrates-substantial-healthcare-cost-reduction-in-patients-with-leptomeningeal-metastases) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-19 11:30 EST — [Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology](https://biopharmsignal.com/news/PSTV/plus-therapeutics-partners-with-ephemeral-technologies-to-deploy-ai-execution-platform-for-cns-oncology) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-15 20:05 EST — [Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout](https://biopharmsignal.com/news/PSTV/plus-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update-on-reyobiqtm-clinical-program-and-cnsider-commercial-rollout) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-08 11:30 EST — [Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases](https://biopharmsignal.com/news/PSTV/plus-therapeutics-announces-oral-presentation-highlighting-reyobiqtm-clinical-and-translational-data-demonstrating-favorable-safety-survival-and-emerging-immunomodulation-in-leptomeningeal-metastases) — Source: PLUS THERAPEUTICS, Inc.